We compare and contrast the expected duration and number of infections and deaths
averted among several designs for clinical trials of COVID-19 vaccine candidates, including …

Controlled human malaria infection (CHMI) is an established model in clinical malaria
research. Upon exposure to Plasmodium falciparum parasites, malaria‐naive volunteers …

Background Malaria-associated anaemia, arising from symptomatic, asymptomatic and
submicroscopic infections, is a significant cause of morbidity worldwide. Induced blood …

Babesiosis is a tick-borne disease caused by intraerythrocytic Babesia parasites. It is a well-
known illness in companion animals and livestock, resulting in substantial economic losses …

Aims This first‐in‐human clinical trial of P218, a novel dihydrofolate reductase inhibitor
antimalarial candidate, assessed safety, tolerability, pharmacokinetics and food effects in …

Two malaria parasite species, Plasmodium falciparum (Pf) and P. vivax (Pv) are responsible
for most of the disease burden caused by malaria. Vaccine development against this …

Vaccines can be extremely cost-effective public health measures. Unfortunately the research
and development (R&D) of novel vaccines is suffering from rising costs and declining …

Much of the gain in malaria control, in terms of regional achievements in restricting
geographical spread and reducing malaria cases and deaths, can be attributed to large …

The complexity of the Plasmodium parasite and its life cycle poses a challenge to our
understanding of the host immune response against malaria. Studying human immune …

Professional antigen-presenting cells (APCs), like macrophages (Mϕs) and dendritic cells
(DCs), are central players in the induction of natural and vaccine-induced immunity to …